ArticleBMC gastroenterology2022
The monocyte to lymphocyte ratio not only at baseline but also at relapse predicts poor outcomes in patients with hepatocellular carcinoma receiving locoregional therapy.
Article in BMC gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Monocyte-to-lymphocyte ratio as a predictor of outcomes in patients with hepatocellular carcinoma.Frontiers in oncology · 2026Pooled it
- The prognostic value of systemic inflammation response index in digestive system carcinomas: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Efficacy of transarterial chemoembolization combined with PD-1 versus PD-L1 inhibitors in mass-forming intrahepatic cholangiocarcinoma: a multicenter retrospective study.Translational cancer research · 2026Article
- Impact of inflammatory biomarkers and surgical interventions on one-month recovery after rib fractures: a propensity-matched cohort study.BMC surgery · 2026Article
- Prognostic Significance of Complete Blood Counts-Derived Inflammatory Markers in Compensated Hepatocellular Carcinoma.Journal of inflammation research · 2026Article
- Prognostic significance of dynamic changes in systemic inflammatory markers on mortality after liver transplantation: a retrospective cohort study.International journal of medical sciences · 2026Article
- Association between monocyte-to-lymphocyte ratio and metabolic dysfunction-associated steatotic liver disease and hepatic steatosis: evidence from NHANES 2017-2020.Translational gastroenterology and hepatology · 2026Article
- Pathogen distribution, antimicrobial resistance, and gut microbiota dysbiosis in patients with cirrhosis complicated by infection in northwestern China.Frontiers in microbiology · 2026Article
- Impact of inflammatory biomarkers and surgical interventions on one-month recovery after rib fractures: A propensity-matched cohort study.Surgery open science · 2025Review
- Identification of optimal biomarkers associated with distant metastasis in breast cancer using Boruta and Lasso machine learning algorithms.BMC cancer · 2025Article
- Concordance Index-Based Comparison of Inflammatory and Classical Prognostic Markers in Untreated Hepatocellular Carcinoma.Journal of clinical medicine · 2025Article
- Scoring Pulmonary Fibrosis Following COVID-19 Pneumonia with Quantitative HRCT: Relationship with Clinical Parameters, Mean Platelet Volume and Lymphocyte/Monocyte RatioThoracic research and practice · 2025Article
- A prediction model based on machine learning: prognosis of HBV-induced HCC male patients with smoking and drinking habits after local ablation treatment.Frontiers in immunology · 2025Article
- Risk Factors for Recurrence in Patients with Hepatocellular Carcinoma After Curative Resection or Ablation.Journal of hepatocellular carcinoma · 2025Review
- The clinical value of PLR, NLR, and MLR in predicting mortality risk in hospitalized patients.Frontiers in pharmacology · 2025Article
- Prognostic Role of Lymphocyte-to-Monocyte Ratio (LMR) in Patients with Intermediate-Stage Hepatocellular Carcinoma (HCC) Undergoing Chemoembolizations (DEM-TACE or cTACE) of the Liver: Exploring the Link between Tumor Microenvironment and Interventional Radiology.Diseases (Basel, Switzerland) · 2024Article
- Article
- The Effect of Low HBV-DNA Viral Load on Recurrence in Hepatocellular Carcinoma Patients Who Underwent Primary Locoregional Treatment and the Development of a Nomogram Prediction Model.Microorganisms · 2024Article
- Article
- Association between monocyte-to-lymphocyte ratio and prostate cancer in the U.S. population: a population-based study.Frontiers in cell and developmental biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundMonocyte to lymphocyte ratio (MLR) represents a pro-inflammatory immune microenvironment. The aim of this study was to elucidate the effect of MLR and subsequent MLR when relapse occurred (R-MLR) on prognosis for hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE) combined with ablation.
methodsA prospective analysis was conducted on 606 patients with HCC who were treated with TACE combined with local ablation in Beijing You'an Hospital affiliated to Capital Medical University from January 1, 2012 to December 31, 2016. MLR or R-MLR were stratified according to the optimal cut-off values. The cumulative recurrence-free survival (RFS), overall survival (OS) , and recurrence-death survival (RDS) rates were calculated by Kaplan-Meier method. The Cox proportion hazard model and logistic regression analysis was conducted to screen for independent predictive factors for indicating early relapse and long-term prognosis.
resultsHigh MLR was significantly associated with relapse, early recurrence, and overall survival. After a median follow-up of 59.4 months, The cumulative 1-, 3-, 5-year RFS rates of low MLR were 74.6%, 43.8%, and 34.0%; while 66.1%, 32.2%, and 22.6% for high group (P < 0.001). There were also significant differences in corresponding OS rates of the two groups (P = 0.003). The cumulative 1-, 3-, 5-year OS rates of low R-MLR were 99.5%, 87.2%, 75.5%; while 98.3%, 78.3%, 61.7% for high group (P < 0.001). There were also significant differences in corresponding RDS rates in the two groups (P = 0.008). 436 patients were divided into four groups on the base of cut-off values of MLR and R-MLR (low-low, low-high, high-low, and high-high). The low-low group has shown better outcomes including the cumulative 1-, 3-, 5-year OS, and RDS rates(P < 0.001).
conclusionsHigh MLR was related to unfavorable outcome. Subsequent change of MLR between baseline and HCC relapse could indicate poor long-term survival after relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.